JPMorgan Chase & Co. (NYSE:JPM) CFO Marianne Lake sold 4,879 shares of JPMorgan Chase & Co. stock in a transaction dated Monday, April 14th. The stock was sold at an average price of $54.89, for a total transaction of $267,808.31. Following the completion of the sale, the chief financial officer now directly owns 29,280 shares of the company’s stock, valued at approximately $1,607,179. JPMorgan Chase & Co. (NYSE:JPM) shares after opening at $55.34 moved to $55.57 on last trade day and at the end of the day closed at $55.22. Company price to sales ratio in past twelve months was calculated as 3.99. JPMorgan Chase & Co. (NYSE:JPM) showed a negative weekly performance of -3.80%.
Walgreen Company (NYSE:WAG) Insider Kermit Crawford sold 74,287 shares of the stock in a transaction that occurred on Tuesday, April 15th. The shares were sold at an average price of $66.01, for a total transaction of $4,903,684.87. Following the sale, the insider now directly owns 90,166 shares of the company’s stock, valued at approximately $5,951,858. Walgreen Company (NYSE:WAG) shares advanced 0.89% in last trading session and ended the day on $66.75. WAG return on equity ratio is recorded as 13.80% and its return on assets is 7.50%. Walgreen Company (NYSE:WAG) yearly performance is 40.08%.
Athenahealth (NASDAQ:ATHN) Insider Stephen N. Kahane sold 10,000 shares of athenahealth stock in a transaction that occurred on Wednesday, April 16th. The shares were sold at an average price of $143.96, for a total value of $1,439,600.00. Following the completion of the sale, the insider now directly owns 69,285 shares in the company, valued at approximately $9,974,269. Athenahealth, Inc. (NASDAQ:ATHN) shares moved down -1.55% in last trading session and was closed at $145.58, while trading in range of $142.24 – $149.01. athenahealth, Inc. (NASDAQ:ATHN) year to date (YTD) performance is 8.24%.
Gilead Sciences (NASDAQ:GILD) Director John Francis Cogan sold 5,000 shares of the stock on the open market in a transaction that occurred on Tuesday, April 8th. The shares were sold at an average price of $70.55, for a total value of $352,750.00. Following the completion of the sale, the director now directly owns 39,542 shares in the company, valued at approximately $2,789,688. Gilead Sciences, Inc. (NASDAQ:GILD) weekly performance is 6.90%. On last trading day company shares ended up $70.00. Gilead Sciences, Inc. (NASDAQ:GILD) distance from 50-day simple moving average (SMA50) is -8.85%. Analysts mean target price for the company is $97.67.